Acknowledgement
이 논문은 2021년도 한국연구재단의 지원을 받아 수행된 기초연구사업인 중견연구(No. NRF-2018R1A2B6009621)의 지원을 받아 수행된 과제임.
References
- Rosas IO, Dellaripa PF, Lederer DJ, Khanna D, Young LR, Martinez FJ. Interstitial lung disease: NHLBI workshop on the primary prevention of chronic lung diseases. Annals of the American Thoracic Society 2014;11(Supplement 3):S169-S77. https://doi.org/10.1513/AnnalsATS.201312-429LD
- Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive- fibrosing interstitial lung diseases. European Respiratory Review 2018;27(150):180076. https://doi.org/10.1183/16000617.0076-2018
- Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. The Lancet 2017;389(10082):1941-52. https://doi.org/10.1016/S0140-6736(17)30866-8
- Network IPFCR. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. New England Journal of Medicine 2012;366(21):1968-77. https://doi.org/10.1056/NEJMoa1113354
- Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS /JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American journal of respiratory and critical care medicine 2011;183(6):788-824. https://doi.org/10.1164/rccm.2009-040GL
- Saito S, Alkhatib A, Kolls JK, Kondoh Y, Lasky JA. Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF). Journal of thoracic disease 2019;11(Suppl 14):S1740. https://doi.org/10.21037/jtd.2019.04.62
- Son JY, Choi KH, Yoo HJ, Kwon OG, Park K, Kim HJ, et al. A Clinical Case Report of Diffuse Interstitial Lung Disease. The Journal of Internal Korean Medicine 2008;fal:111-6.
- Ahn JM, Joo HJ, Park JH, Park JW, Kim KI, Jung HJ, et al. The Effects of Lung-Moistening Herbal Medicines on Bleomycin-Induced Pulmonary Fibrosis Mouse Model. Processes 2020;8(1):102. https://doi.org/10.3390/pr8010102
- 전국한의과대학 폐계내과학교실. 폐계내과학. 서울: 도서출판 나도; 2019, p. 464.
- Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012;67(5):407-11. https://doi.org/10.1136/thoraxjnl-2011-201184
- Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. European Respiratory Journal 2010;35(4):830-6. https://doi.org/10.1183/09031936.00155108
- du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. European Respiratory Journal 2014;43(5):1421-9. https://doi.org/10.1183/09031936.00131813
- Ichikado K, Suga M, Mul er NL, Taniguchi H, Kondoh Y, Akira M, et al. Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and nonsurvivors. American journal of respiratory and critical care medicine 2002;165(11):1551-6. https://doi.org/10.1164/rccm.2106157
- Oda K, Ishimoto H, Yatera K, Naito K, Ogoshi T, Yamasaki K, et al. High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respiratory research 2014;15(1):1-9.
- Kwon BS, Song JW. New Diagnostic Guidelines for Idiopathic Pulmonary Fibrosis. Korean Journal of Medicine 2019;94(2):173-81. https://doi.org/10.3904/kjm.2019.94.2.173
- Uh ST. Idiopathic Pulmonary Fibrosis: New Concept of Pathogenesis and Treatment. J Korean Med Assoc 2009;52(1):22-9. https://doi.org/10.5124/jkma.2009.52.1.22
- Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. American journal of respiratory and critical care medicine 2000;161(4):1172-8. https://doi.org/10.1164/ajrccm.161.4.9907002
- Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. British Medical Journal 1990;301(6759):1015-7. https://doi.org/10.1136/bmj.301.6759.1015
- Baek HJ, Bhang YH, Kim JH, Kim SJ, Kim KI, Lee BJ, et al. A Retrospective Study of Chronic Pulmonary Disease Patients Treated with Chungsangboha-tang : IgE, eosinophil, PFT. J Int Korean Med 2016;37(3):484-94.
- Jung HJ, Jung GJ, Jung SK, Rhee HK. Liripois Tuber contributes to the chemotaxis of eosinophils and secretion of cytokines in A549 human epithelial cells. The Journal of Korean Oriental Chronic Disease 2005;10(1):1-20.
- 張介賓, 景岳全書. 서울: 한미의학; 2006.
- Collard HR. King Jr TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 2003; 168(5):538-42. https://doi.org/10.1164/rccm.200211-1311OC